RT Journal Article
SR Electronic
T1 Towards adaptive deep brain stimulation: clinical and technical notes on a novel commercial device for chronic brain sensing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.10.21251638
DO 10.1101/2021.03.10.21251638
A1 Yohann Thenaisie
A1 Chiara Palmisano
A1 Andrea Canessa
A1 Bart J. Keulen
A1 Philipp Capetian
A1 Mayte Castro Jiménez
A1 Julien F. Bally
A1 Elena Manferlotti
A1 Laura Beccaria
A1 Rodi Zutt
A1 Grégoire Courtine
A1 Jocelyne Bloch
A1 Niels A. van der Gaag
A1 Carel F. Hoffmann
A1 Eduardo Martin Moraud
A1 Ioannis U. Isaias
A1 M. Fiorella Contarinoe
YR 2021
UL http://medrxiv.org/content/early/2021/03/12/2021.03.10.21251638.abstract
AB Background Technical advances in deep brain stimulation (DBS) are crucial to improve therapeutic efficacy and battery life. A prerogative of new devices is the recording and processing of a given input signal to instruct the delivery of stimulation.Objective We studied the advances and pitfalls of one of the first commercially available devices capable of recording brain local field potentials (LFP) from the implanted DBS leads, chronically and during stimulation.Methods We collected clinical and neurophysiological data of the first 20 patients (14 with Parkinson’s disease [PD], five with various types of dystonia, one with chronic pain) that received the Percept™ PC in our centers. We also performed tests in a saline bath to validate the recordings quality.Results The Percept PC reliably recorded the LFP of the implanted site, wirelessly and in real time. We recorded the most promising clinically useful biomarkers for PD and dystonia (beta and theta oscillations) with and without stimulation. Critical aspects of the system are presently related to contact selection, artefact detection, data loss, and synchronization with other devices. Furthermore, we provide an open-source code to facilitate export and analysis of data.Conclusion New technologies will soon allow closed-loop neuromodulation therapies, capable of adapting the stimulation based on real-time symptom-specific and task-dependent input signals. However, technical aspects need to be considered to ensure clean synchronized recordings. The critical use by a growing number of DBS experts will alert new users about the currently observed shortcomings and inform on how to overcome them.Competing Interest StatementPC: Consulting and speaking fees and unrestricted grants from BostonScientific. Consulting and speaking fees from Brainlab IUI: Speaking fees from Medtronic PLC; unrestricted grants from Newronika Srl paid to Institution MFC: Advisory board and speaking fees from BostonScientific; unrestricted grants, advisory board, speaking fees and consultancies from Medtronic; consultancy from CHDR, grants from AbbVie, in-kind contribution from Global Kinetics Corporation, outside the submitted work. All fees are paid to Institution.Funding StatementCP and IUI were sponsored by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Project-ID 424778381, TRR 295. YT and EMM were funded by the Swiss National Science Foundation (Ambizione fellowship PZ00P3_180018), the Parkinson Schweiz foundation (project OPTIM-GAIT) and the European Union H2020 program (Marie Sklodowska Curie Individual Action MSCA-IF-2017-793419) and the Gustaaf Hamburger funds of the Foundation Philantropia (Project 'Remarcher') The authors wish to declare that the Medtronic PLC company had no impact on study design, patient selection, data analysis, or reporting of the resultsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Medical ethical committee Leiden Den Haag Delft, the Ethik-Kommission of the University Hospital Würzburg and the Ethical Committee of the Canton of Vaud (CER-VD) approved the respective studies and/or waived review for the data collection of the respective center. All patients gave written informed consent according to the Declaration of Helsinki. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData collected in the three centers are available from the respective senior authors at a reasonable request. The software is available at github.com https://github.com/YohannThenaisie/PerceptToolbox.git